Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

1 Deal Arena Investors Might Have Missed

By Max Macaluso and Dave Williamson - Nov 29, 2012 at 6:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But don't celebrate just yet.

Arena Pharmaceuticals (Nasdaq: ARNA) is best known for its weight-loss drug, Belviq, which is slated to hit the U.S. market soon. Its main competition will be VIVUS' (Nasdaq: VVUS) Qsymia, and a third biotech -- Orexigen Therapeutics (Nasdaq: OREX) -- continues to work toward approval from the Food and Drug Administration for its obesity drug, Contrave.

Arena struck a deal last quarter with South Korean company Ildong to commercialize Belviq in South Korea. Arena is getting $5 million for the deal and will be entitled to more payouts if further milestones are reached.

Recently, Arena expanded its relationship with Ildong to include temanogrel, a drug in the early phases of development that will be aimed at treating arterial thrombosis. In this video, Motley Fool health care analysts Max Macaluso and David Williamson break down this news and discuss why it's too early for investors to start celebrating this deal.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
$49.55 (-6.81%) $-3.62
VIVUS, Inc. Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.